Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zipalertinib plus Chemotherapy vs Chemotherapy in EGFR Exon 20 Insertion NSCLC
2023-503575-21-00Phase 3Authorised
- Sponsor
- Taiho Oncology
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Taiho Oncology. Planned start Nov 2023; status: authorised.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503575-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503575-21-00.